Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
24 déc. 2022 00h01 HE
|
Coherus BioSciences, Inc.
- FDA has been unable to travel to China to conduct the required site inspection resulting in delayed action on the BLA - - Coherus and Junshi Biosciences are actively engaged in ongoing discussions...
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
08 nov. 2022 16h01 HE
|
Coherus BioSciences, Inc.
– UDENYCA® net sales of $45.4 million in the third quarter 2022 –– CIMERLI™ launched in the United States on October 3rd –– Planning underway for 2023 commercial launches of toripalimab, YUSIMRY™ and...
Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022
01 nov. 2022 07h30 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2022 financial results will be released after...
Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology
12 oct. 2022 07h30 HE
|
Coherus BioSciences, Inc.; Shanghai Junshi Biosciences Co., Ltd
– Toripalimab in combination with chemotherapy was associated with significant improvements in PFS and OS compared with chemotherapy alone in patients with advanced NSCLC without EGFR/ALK mutations,...
Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022
19 sept. 2022 07h30 HE
|
Coherus BioSciences, Inc.
- CIMERLI is the first and only FDA-approved biosimilar interchangeable with Lucentis® (ranibizumab injection) for all indications, with 12 months of interchangeability exclusivity - -...
Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference
12 sept. 2022 08h30 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will participate at the H.C. Wainwright 24th...
Coherus BioSciences Announces New Employment Inducement Grants
29 août 2022 20h49 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 24, 2022, the compensation...
Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update
04 août 2022 16h01 HE
|
Coherus BioSciences, Inc.
– Commercial launch of CIMERLI™ planned for early October 2022 –– PDUFA date for toripalimab BLA is December 23, 2022 –– Commercial preparation underway for planned July 2023 launch of...
FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity
02 août 2022 19h15 HE
|
Coherus BioSciences, Inc.
- CIMERLI™ is Coherus’ third FDA-approved product and the first of four new product launches planned by the end of 2023 - - First CIMERLI™ product sales expected in October 2022 - - COLUMBUS AMD...
Coherus BioSciences Announces New Employment Inducement Grants
01 août 2022 23h15 HE
|
Coherus BioSciences, Inc.
REDWOOD CITY, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective August 1, 2022, the compensation...